THTX Theratechnologies Inc.

Nasdaq theratech.com


$ 3.39 $ 0.00 (0 %)    

Thursday, 25-Sep-2025 15:59:56 EDT
QQQ $ 605.60 $ 0.00 (0 %)
DIA $ 463.78 $ 0.00 (0 %)
SPY $ 667.64 $ 0.00 (0 %)
TLT $ 90.92 $ 0.00 (0 %)
GLD $ 390.11 $ 0.00 (0 %)
$ 3.39
$ 3.36
$ 3.27 x 2
$ 3.63 x 10
-- - --
$ 1.12 - $ 3.40
3,272,893
na
155.87M
$ 0.70
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 theratechnologies-obtains-final-court-approval-of-proposed-plan-of-arrangement-to-be-acquired-by-future-pak-co-expects-that-the-arrangement-will-be-completed-on-or-about-september-25-2025

MONTREAL, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX...

 theratechnologies-shareholders-approve-acquisition-by-cb-biotechnology

Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX: TH) (NASDAQ: THTX), a commercial-stage biop...

Core News & Articles

https://www.bloomberg.com/news/articles/2025-08-04/south-africa-gates-step-in-after-us-defunds-hiv-research

 theratechnologies-q2-eps-009-misses-002-estimate-sales-17729m-beat-17547m-estimate

Theratechnologies (NASDAQ:THTX) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $...

 jones-trading-downgrades-theratechnologies-to-hold

Jones Trading analyst Justin Walsh downgrades Theratechnologies (NASDAQ:THTX) from Buy to Hold.

 us-stocks-likely-to-open-higher-as-trump-announces-vietnam-trade-deal-sp-500s-golden-cross-reason-to-expect-better-than-average-returns-says-expert

U.S. stock futures were slightly higher on Thursday after a mixed close on Wednesday. Futures of major benchmark indices were t...

 reported-earlier-theratechnologies-enters-definitive-agreement-to-be-acquired-by-cb-biotechnology-for-301-per-share-plus-contingent-value-right

Offer of US$3.01 in cash plus one contingent value right for potential additional aggregate payments of up to US$1.19 per share...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION